

Full Length Research Paper

Evaluation of immunogenic properties of monovalent and polyvalent inactivated bovine virus diarrhea virus (BVDV) vaccines

Vladimir S. Kurcubic^{1*}, Nenad S. Milic², Radojica D. Djokovic¹ and Zoran Z. Ilic³

¹Department of Animal Science, Faculty of Agronomy, Cacak, Cara Dusana 34, 32.000 Cacak, University of Kragujevac, Serbia.

²Department of Microbiology, Faculty of Veterinary Medicine, University of Belgrade, Bulevar oslobođenja 18, 11.000 Belgrade, Serbia.

³Department of Animal Science, Faculty of Agriculture, University of Prishtina - Zubin Potok, Jelene Anzujske bb, Serbia.

Accepted 23 June, 2011

This study is aimed at evaluating the immunogenicity of two inactivated (mono- and polyvalent) vaccines containing bovine virus diarrhea virus (BVDV) reference and field strains. Three experimental groups were formed: 10 calves vaccinated twice (days 1 and 28) subcutaneously (s/c) with 2 ml of inactivated polyvalent vaccine per animal (Group 1); 10 calves vaccinated twice (days 1 and 28) subcutaneously (s/c) with 2 ml of inactivated monovalent vaccine per animal (Group 2) and 9 unvaccinated calves (Control, Group C). Blood sera were obtained from immunized animals (standard procedure: on days 0, 14, 28, 42 and 56 post-immunization). Geometric mean titer (GMT) values for BVDV neutralizing antibodies were substantially higher in blood sera of calves receiving the inactivated monovalent vaccine. The immune response developed more rapidly in calves immunized with the monovalent vaccine.

Key words: Bovine virus diarrhea virus, immunogenic properties, inactivated vaccines.

INTRODUCTION

Bovine virus diarrhea virus (BVDV) is a member of the genus *Pestivirus* within the family *Flaviviridae*. BVDV causes infections of domestic and wild ruminants worldwide and significant economic losses to the cattle industry (Baker, 1995; Brownlie, 1991). BVDV is classified into one of two biotypes, cytopathic (CP) or non-cytopathic (NCP). Based on antigenic and genetic properties, two genotypes of the causative virus have been identified, BVDV-1 and BVDV-2: BVDV-2 makes up about 50% of the isolates in North America, whereas BVDV-1 predominates throughout Europe, with more than 90% (Ridpath, 2005; Vilcek et al., 2005). BVDV-1 and BVDV-2 genotypes have been further subdivided into subgenotypes BVDV-1a, BVDV-1b, BVDV-2a and BVDV

2b in North America (Flores et al., 2002; Ridpath et al., 2000). Another classification describes 11 genetic groups of BVDV (Vilcek 2001). The major economic losses due to BVDV infection include reduced fertility, abortions and the generation of persistent viremic calves, which can develop fatal "mucosal disease" (Bielefeldt, 1995; Brownlie, 1990). Persistently infected (PI) live long-term virus carriers play the key role in BVDV epidemiology. Control of BVDV infection/diseases includes both: 1) biosecurity to prevent entry of PI animals into the herd by testing cattle for BVDV, and 2) vaccines as part of routine immunization programs. These viral vaccines may be modified live virus (MLV), inactivated or chemically altered live virus vaccines (Hjerpe, 1990). The disadvantages of modified live BVDV-containing vaccines include the following: utmost care needed when using and handling this vaccine in order to prevent inactivation, possible contamination with other viruses (Moennig et al.,

*Corresponding author. E-mail: vladevet@tfc.kg.ac.rs.

2005), probability of development of postvaccinal mucosal disease (Lambert, 1973), not recommended for pregnant animals (transplacental infections) due to insufficient reliability (Kelling, 1996), possible vaccine strain shedding and introduction of new BVDV strains into herds, and the development of immunosuppression as induced by the vaccinal strain of the virus (Roth and Kaerberle, 1983).

The disadvantages associated with inactivated BVDV vaccines include: higher price, necessity of revaccination (Brock and Chase, 2000), a longer period required to develop immunity (Bolin, 1995), possible anaphylactic and local reactions at the vaccination site, shorter duration of immunity, and the immune response being directed only against certain antigen variants of the virus (Kelling, 1996; Bolin et al., 1991). The purpose of this study is to determine the ability of the experimental inactivated vaccines containing BVDV immunogens to induce neutralizing antibodies to type 1 BVDV strains in vaccinated calves. Two different experimental vaccines (monovalent and polyvalent) were evaluated using detection of virus neutralizing antibodies, as a measure of their immunogenicity in calves.

MATERIALS AND METHODS

Animals

Normal healthy beef calves (Simmental race) of mixed sex were used. The calves were 6 to 7 months of age. The vaccinated calves were subjected to cohabitation with the unvaccinated animals (control group) in order to determine the possible transmission of vaccine virus to unvaccinated animals. During the experiment, the calves were kept in a closed building, in free stalls, on slatted floor, under conditions common in intensive calf rearing.

Vaccine preparation

Monovalent inactivated vaccine - lot 251200. Reference CP strain NADL, infective titer $\log 10^{-6}$ TCID₅₀/0.1 ml (CVL Weybridge, provided by Dr. Georgina Ibatá) was grown at the MDBK (Madin Darby bovine kidney) cell line. The suspension of the harvested NADL strain of BVDV was heated at 37°C and inactivated by adding β -propiolactone (diluted in cold distilled water 1:1.000). The inactivation process was followed by rolling (IKA WERKE 200 rpm/min⁻¹) for 3 h at 37°C. The total inactivation of the BVDV harvested virus was controlled in accordance with European Pharmacopoeia 5.0., monograph: Bovine diarrhoea vaccine (inactivated) No 01/2005:1952 (Tests, Inactivation, p. 734). The harvested inactivated virus was used in the volume sufficient for 10 doses of vaccine and inoculated in two passages, each of which was observed for 10 days. No live virus was detected in the cell line during the test. The suspension of inactivated virus was stored at -20°C (the volume of the inactivated virus sample was 65.25 ml). The pH of the suspension following inactivation was 4.57, and was adjusted to 7.4 using 1M NaOH (0.6 ml). The suspension was assayed for sterility using thioglycolate broth, nutrient agar, nutrient broth and Sabouraud broth incubated at 37 and 25°C for 14 days. The assay confirmed sterility of the above suspension. Merthiolate preservative (1:10.000 to 0.7 ml 1% v/v) was added to the inactivated virus sample. At a pH of 7.56, 21.7 ml of sterile 25% Al(OH)₃ and 0.29 ml of sterile 20% aqueous solution of saponin

(MERCK) were added at a ratio of 1:1.500 to suspension of the inactivated BVDV vaccine strain. The volume of the prepared monovalent vaccine against BVDV infection in cattle was 87.94 ml. The pH of the vaccine - lot 251200 was 8.07 (Cheerer HANA). Sterility assay of the prepared vaccine was conducted in the same manner as that of the suspension.

The assays confirmed sterility of the vaccine sample. Polyvalent inactivated vaccine - lot 270700. Five cp BVDV strains were used for the preparation of the polyvalent inactivated vaccine:

- 1) W1. - 162903, virus titer $\log 10^{-6}$ TCID₅₀/0.1 ml, 27 ml.
- 2) W2. - 172984, virus titer $\log 10^{-5}$ TCID₅₀/0.1 ml, 30 ml.
- 3) W3. - 173481, virus titer $\log 10^{-5}$ TCID₅₀/0.1 ml, 30 ml.
- 4) W4. - 179725, virus titer $\log 10^{-5}$ TCID₅₀/0.1 ml, 30 ml.

The strains are all BVDV type 1 isolated in the United Kingdom in the 1980s. Monoclonal antibody typing procedure reveals that they are quite distinct.

- 5) Local BVDV field isolate, derived from a calf suffering from mucosal disease (MD) and identified by standard VN test, with virus titer $\log 10^{-5}$ TCID₅₀/0.1 ml, 30 ml.

All five CP BVDV strains were cultivated at the MDBK cell line. The virus suspension was inactivated by adding β -propiolactone (final concentration 1:1.000), which was followed by rolling (IKA WERKE 200 rpm/min⁻¹) for 3 h at 37°C. The pH of the suspension following inactivation was adjusted to 7.4 using 1M NaOH. Prior to virus inoculation, the MDBK cell line was checked for the presence of the BVD virus. The test was performed following the procedure European Pharmacopoeia 5.0., procedure named: Cell cultures for the production of veterinary vaccines No 01/2005:50204 chapter 5.2.4.; p. 458/459 (detection of specified viruses), using fluorescein conjugated antibodies (BVD) with the presence of a positive control cell line. The MDBK cell line was negative for the BVD virus. The suspension was assayed for sterility using thioglycolate broth, nutrient agar, nutrient broth and Sabouraud broth incubated at 37 and 25°C for 14 days. The assay confirmed sterility of the aforementioned suspension. Upon inactivation of the viral suspension, 1% merthiolate (final concentration 1:10.000) was added to the suspension. Inactivated antigens were adsorbed on sterile Al(OH)₃ by adding 25% sterile adjuvant twice, which was followed by continuous rolling on a magnetic mixer. During the process, the vaccine suspension samples were made of 135 ml CP BVDV strains and 33.8 ml Al(OH)₃ to obtain a volume of 173 ml. A total of 0.6 ml of the second adjuvant, saponin (MERCK, 20%) was added to the sample, making the final concentration in the vaccine of 1:1.500. The pH of the prepared vaccine - lot 270700 was 7.39. The sterility assay of the prepared vaccine was conducted in the same manner as that of the suspension. The assay confirmed sterility of the vaccine sample.

Vaccine trials

All 29 calves in vaccine trials were seronegative before the initial vaccination on day 0, as detected by the virus neutralization test. The calves were divided into three experimental groups. Group 1 consisted of 10 male calves vaccinated twice (on days 0 and 28) subcutaneously (s/c) with 2 ml of the inactivated polyvalent vaccine per animal. 10 calves (7 males and 3 females) constituting Group 2 were inoculated twice (on days 0 and 28) subcutaneously (s/c) with 2 ml of the inactivated monovalent vaccine per animal. The control group (C) contained 9 unvaccinated female calves.

Serum collection

Blood sera were collected, frozen and stored at -20°C until assayed for antibodies. The collection of the blood sera from the

Table 1. Serum antibody titers to BVDV in the calves receiving the polyvalent vaccine (Group 1).

Calf serial number	VNT Ab titer on day 0/GMT	VNT Ab titer on day 14/GMT	VNT Ab titer on day 28/GMT	VNT Ab titer on day 42/GMT	VNT Ab titer on day 56/GMT
1	0	0	0	1:16	5
2	0	0	0	0	1
3	0	0	0	1:16	2
4	0	0	1:4	1:64	7
5	0	0	0	1:32	5
6	0	0	0	1:8	4
7	0	0	0	1:16	4
8	0	0	0	1:8	3
9	0	0	0	1:32	5
10	0	0	0	0	4
GMTlog ₂	0	0	0.20	3.40	4.00

calves of both Groups 1 and 2 was performed using standard procedure at bi-weekly intervals (on days 0, 14, 28, 42 and 56 in the vaccine trial). Blood samples for serological testing were taken from the control calves on days 0 and 56 of the experiment.

Virus neutralization test

The collected blood sera were tested by virus neutralization test (VNT) in cell cultures using Nunclon plates. The virus used was CP strain NADL, virus titer log 10⁶ TCID₅₀/0.1 ml (CVL, Weybridge). Cell line: MDBK, Brescia. The samples of blood sera were inactivated for 30 min at 56°C. Preliminary testing was performed using twofold dilutions of the blood sera of 1:2 through 1:1024. 25 µl of the blood sera was incubated with 25 µl 100 TCID₅₀ BVDV CP strain NADL for 1 h at 37°C. Following incubation, 50 µl of MDBK cell suspension was added at a concentration of 3 x 10⁵ cells/ml. The inoculated cell line was incubated for 4 days at 37°C, and neutralization of CP strain infectivity was detected by observation of viral cytopathology. On day 4, all blood sera that exhibited neutralizing viral activity in the 1:8 solution were titrated to 1:1024. The endpoint dilution of the blood sera that completely neutralized the BVDV virus and prevented the development of the cytopathogenic effect (CPE) was the specific virus-neutralizing antibody titer of the blood sera samples. The

results obtained herein were calculated by statistical methods as logarithms of the reciprocal of the serum dilution (log₁₀) for VNT expressed as geometric mean titers (GMTlog₂) as described earlier by Brugh (1978).

RESULTS

Prior to vaccination (on the first day of immunization), all animals in each of the three experimental groups were seronegative for BVDV. At the end of the immunization trial (on day 56), all calves of the control group were still seronegative. The samples of blood sera of the seronegative calves receiving the polyvalent inactivated vaccine (Group 1) were tested on the presence and titer of the antibodies to BVDV by a VNT and summarized in Table 1. This study presents individual animals and their respective antibody titers to BVDV NADL strain on blood sera collection on days 0, 14, 28, 42 and 56. In all animals, no neutralization occurred on days 0 and 14 (GMTlog₂ = 0). At revaccination (conducted 28 days after vaccination), one animal (1/10) from Group 1 tested seropositive, with BVDV-specific

antibody titers of 1:4. Eight of the ten (8/10) calves vaccinated with the polyvalent vaccine on day 0 and revaccinated with same vaccine on day 28 were positive for BVDV specific antibodies on day 42 of blood sera collection. The antibody titers induced by the polyvalent vaccines ranged from 0 to 1:64. At the end of the immunization trial (on day 56), all calves in Group 1 were seropositive. The specific antibody titers against BVDV in the blood sera were within the 1:2 to 1:128 range. From days 28 to 56 of the immunization trial, GMTlog₂ values increased continuously (0.2, 3.40 and 4.00). The antibody responses to CP NADL strain BVDV found in the blood sera of the seronegative calves receiving the monovalent vaccine (Group 2) were assessed by the VNT and summarized in Table 2. In all test animals, no neutralization occurred on days 0 and 14 (GMTlog₂ = 0). At revaccination, five animals (5/10) from Group 2 tested seropositive, with BVDV-specific antibody titers ranging from 0 to 1:16. All of the ten calves vaccinated with the monovalent vaccine on day 0 and revaccinated with the same vaccine on day 28 showed a BVDV

Table 2. Serum antibody titers to BVDV in the calves receiving the monovalent vaccine (Group 2).

Calf serial number	VNT Ab titer on day 0/GMT	VNT Ab titer on day 14/GMT	VNT Ab titer on day 28/GMT	VNT Ab titer on day 42/GMT	VNT Ab titer on day 56/GMT
1	0	0	0	1:32	5
2	0	0	1:2	1:8	3
3	0	0	0	1:512	9
4	0	0	0	1:256	8
5	0	0	1:4	1:256	8
6	0	0	1:16	1:128	7
7	0	0	1:4	1:128	7
8	0	0	1:2	1:512	9
9	0	0	0	1:256	8
10	0	0	0	1:128	7
GMTlog ₂	0	0	1.00	7.10	6.20

specific antibody response on collection day 42. The antibody titers induced by the monovalent vaccine ranged from 1:8 to 1:512. At the end of the immunization trial (on day 56), all calves were seropositive. The specific antibody titers against BVDV in the blood sera obtained from Group 2 animals ranged from 1:4 to 1:256. The GMTlog₂ values highly increased between 28 and 42 days – reaching their peak values of 1.00 to 7.10 log₂) and slightly declined 56 days after vaccination (6.20 log₂).

Statistical evaluation of the results obtained included the initial formation of statistical base which composed of 3 variables - trial day, experimental group and log-transformed values of specific antibody titers to BVDV (GMTlog₂) - that was used in an individual LSD test - the least significant difference test, performed by means of a commercial statistical software (SPS statistical software ver. 5.0). The LSD test results are given in tabular form (Table 3). The geometric means titers (GMTlog₂) for each treatment group were compared for significant differences between the vaccine groups (1 and 2) at given dates of blood

sera collection. The results on the log-transformed values of specific antibody titers to BVDV (GMTlog₂) for the Groups 1 and 2 animals as analyzed by the LSD test suggest that no significant difference was found between Groups 1 and 2 calves on day 28 post-vaccination, nor between days 42 and 56 in both Groups 1 and 2 animals. Statistically very significant differences of up to 99% were recorded between all other groups (Table 3).

DISCUSSION

Regarding the mentioned hazards, research activities have become more focused on the development of effective inactivated vaccines. In our study we opted for inactivated (mono and polyvalent) vaccines due to their greater safety and ability to provide protection to cattle of almost all ages, bred for different purposes. Previously published observations (Howard et al., 1994) suggested that it is not necessary to use live avirulent virus to achieve protection of the

respiratory tract and that immunity is not dependent on a local immune response. Considering the large volume of literature available on this subject, the personal experience acquired during our research and the identified research tasks that are associated with testing the immunogenicity of mono and polyvalent vaccines against BVDV in beef cattle, special importance was given to adequate selection of BVDV immunogens and CP vaccinal strains. We opted for MDBK cell line because comparison of the five cell cultures for viral antigen production showed that four of the cell cultures (calf testis cells, nasal mucosa line, embryo lung cells and lung-wash cell line) yielded similar amounts of antigen while MDBK cells gave a titer of antigen that was about 16-fold higher than that of the other four (Howard et al., 1994). β-Propiolacton was used for chemical inactivation which was in line with the O.I.E. recommendations (O.I.E., 2000: Manual of Standards for Diagnostic Tests and Vaccines, Chapter X.5., Bovine viral diarrhea). In order to stimulate a stronger immune response, Al(OH)₃ was used as an adjuvant and saponin as the second adjuvant, according to the

ACKNOWLEDGEMENTS

This study is part of the technological development project Ref. No. 31001. "An environmental approach and implementation of modern biotechnologies as a basis for the improvement of ruminant breeding technology", financially supported by the Ministry of Education and Science of the Republic of Serbia.

REFERENCES

- Baker JC (1995). The clinical manifestations of bovine viral diarrhoea infection. *Vet. Clin. N. Am.-Food A.*, 11: 425-45.
- Bielefeldt OH (1995). The pathologies of bovine viral diarrhoea virus infection. A window on the pathogenesis. *Vet. Clin. N. Am.-Food A.*, 11: 447-76.
- Bolin SR (1993). Immunogens of Bovine viral diarrhoea virus. *Vet. Microbiol.*, 37(3-4): 2263-71.
- Bolin SR (1995). Control of bovine viral diarrhoea infections by use of vaccination. *Vet. Clin. N. Am.-Food A.*, 11(3): 615-25.
- Bolin SR, Littlejohn ET, Ridpath JF (1991). Serologic detection and practical consequences of antigenic diversity among bovine viral diarrhoea viruses in a vaccinated herd. *Am. J. Vet. Res.*, 52: 1033-37.
- Brock KV, Chase CCL (2000). Development of a fetal challenge method for the evaluation of bovine viral diarrhoea virus vaccines. *Vet. Microbiol.*, 77(1-2): 209-214.
- Brownlie J (1990). The pathogenesis of bovine virus diarrhoea virus infections. *Rev. Sci. Tech. OIE*, 9: 43-59.
- Brownlie J (1991). Pestiviruses of ruminants (border disease and mucosal disease). Office international des epizooties, 59th general session Paris, 59 SG/10.
- Brownlie J, Clarke MC, Hooper LB, Bell GD (1995). Protection of the bovine fetus from bovine viral diarrhoea virus by means of a new inactivated vaccine. *Vet. Rec.*, 137(3): 58-62.
- Brugh M (1978). A simple Method for Recording and Analyzing Serological Data. *Avian Dis.*, 22(2): 362-365.
- Flores EF, Ridpath JF, Weiblen R, Vogel FSF, Gil Laura HVG (2002). Phylogenetic analysis of Brazilian bovine viral diarrhoea virus type 2 (BVDV-2) isolates: evidence for a subgenotype within BVDV-2. *Virus Res.*, 87: 51-60.
- Fulton RW, Confer AW, Burge LJ, Perino LJ, d'Offay JM, Payton ME, Mock RE (1995). Antibody responses by cattle after vaccination with commercial viral vaccines containing bovine herpesvirus-1, bovine viral diarrhoea virus, parainfluenza-3 virus, and bovine respiratory syncytial virus immunogens and subsequent revaccination at day 140. *Vaccine*, 13(8): 725-33.
- Fulton RW, Lurinda J Burge (2001). Bovine viral diarrhoea virus types 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines. *Vaccine*, 19: 264-274.
- Hjerpe CA (1990). Bovine vaccines and herd vaccination programs. *Vet. Clin. N. Am.-Food A.*, 6: 171-207.
- Howard CJ, Clarke MC, Sopp P, Brownlie J (1994). Systemic vaccination with inactivated bovine virus diarrhoea virus protects against respiratory challenge. *Vet. Microbiol.*, 42: 171-79.
- Kelling CL (1996). Planing bovine viral diarrhoea virus vaccination programs. *Vet. Med.-US.*, 9: 873-77.
- Lambert G (1973). Bovine viral diarrhoea: prophylaxis and postvaccinal reactions. *JAVMA - J. Am. Vet. Med. A.*, 163: 874-76.
- Meyling A, Ronsholt L, Dalsgaard K, Jensen M Astrid (1985). Experimental exposure of vaccinated and non-vaccinated pregnant cattle to isolates of bovine viral diarrhoea virus (BVDV). Agriculture, Pestivirus infection of ruminants: 225-231, A seminar in the CEC programme of coordination of research on animal husbandry, held in Brussels, 10/11 September 1985.
- Moennig V, Houe H and Lindberg Ann (2005). BVD control in Europe: current status and perspectives. *Anim. Health Res. Rev.*, 6(1): 63-74.
- O.I.E. (2000). Manual of Standards for Diagnostic Tests and Vaccines, Chapter X.5, Bovine viral diarrhoea.
- Ridpath JF (2005). Practical significance of heterogeneity among BVDV strains: impact of biotype and genotype 1 and genotype 2 BVDV. *Virology*, 212(1): 259-62.
- Ridpath JF, Neill JD, Frey M (2000). Phylogenetic antigenic and clinical characterization of type 2 BVDV from North America. *Vet. Microbiol.*, 77: 145-155.
- Roth JA, Kaeberle ML (1983). Suppression of neutrophil and lymphocyte function induced by a vaccinal strain of bovine viral diarrhoea virus with or without the administration of ACTH. *Am. J. Vet. Res.*, 44: 2366-2372.
- Vilcek S (2001). Bovine viral diarrhoea virus genotype 1 can be separated into at least eleven genetic groups. *Arch. Virol.*, 146: 99-115.
- Vilcek S, Durkovic B, Kolesarova M and Paton DJ (2005). Genetic diversity of BVDV: consequences for classification and molecular epidemiology. *Prev. Vet. Med.*, 72(1-2): 31-35.